Blueprint Medicines Stock Insider Trading

Healthcare > Biotechnology

Buy BPMC

*Your capital is at risk

$129.46

+0 (+0%)

At Close: Oct 17, 2025

Blueprint Medicines Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -72.66. In total, the insiders bought 235.19K and sold 2.16M BPMC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-72.66
● Buy	235.19K shares
● Sell	2.16M shares
6% Buy Activity Moderate Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 17, 2025 Sell	Common Stock U-Tender	Rossi Christina Chief Operating Officer	C-Suite Officer	20 628 Value: $0
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	80 000 Value: $5.26M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	6 500 Value: $562.9K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	28 500 Value: $1.54M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	26 125 Value: $2.62M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	30 000 Value: $1.84M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	30 000 Value: $1.29M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	30 000 Value: $2.85M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Rossi Christina Chief Operating Officer	C-Suite Officer	26 400 Value: $2.55M
Jul 17, 2025 Buy	Common Stock A-Award	Haviland Kate Chief Executive Officer	CEO / President	129 210 Value: $16.7M
Jul 17, 2025 Sell	Common Stock D-Return	Haviland Kate Chief Executive Officer	CEO / President	224 410 Value: $0
Jul 17, 2025 Sell	Common Stock U-Tender	Haviland Kate Chief Executive Officer	CEO / President	70 729 Value: $0
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	2 Value: $33
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	591 Value: $21.3K
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	39 000 Value: $3.18M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	32 500 Value: $2.81M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	28 500 Value: $1.54M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	26 125 Value: $2.62M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	80 000 Value: $4.90M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	80 000 Value: $3.45M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	80 000 Value: $7.61M
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Haviland Kate Chief Executive Officer	CEO / President	70 400 Value: $6.80M
Jul 17, 2025 Sell	Common Stock D-Return	Borisy Alexis Director	Director	3 902 Value: $0
Jul 17, 2025 Sell	Common Stock U-Tender	Borisy Alexis Director	Director	74 160 Value: $0
Jul 17, 2025 Sell	Stock Option (Right to Buy) D-Return	Borisy Alexis Director	Director	7 500 Value: $523.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BLUEPRINT MEDICINES CORPORATION

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by